David L. Gray

发表

Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences

P. Tobler, E. Fehr, Alexander Soutschek, 2020, Biological Psychiatry.

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

M. Ehlers, P. Tierney, R. Kozak, 2018, Nature Communications.

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated

S. Duvvuri, David L. Gray, U. S. Sohur, 2018, Neurology and Therapy.

The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey

R. Killiany, R. Balice-Gordon, R. Kozak, 2017, Alzheimer's & Dementia.

The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.

R. Mailman, P. Eslinger, Xuemei Huang, 2020, Journal of Parkinson's disease.

Synthesis of 5-bromo-6-methyl imidazopyrazine, 5-bromo and 5-chloro-6-methyl imidazopyridine using electron density surface maps to guide synthetic strategy

David L. Gray, A. Harris, D. Nason, 2011 .

Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors.

N. Barta, David L. Gray, S. Glase, 2008, Bioorganic & medicinal chemistry letters.

Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization.

R. Kozak, David L. Gray, B. Rai, 2018, Journal of medicinal chemistry.

Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.

P. Fish, T. Ryckmans, N. Barta, 2008, Bioorganic & medicinal chemistry letters.

Remarkable [3+2] Annulations of Electron-Rich Olefins with Unstabilized Azomethine Ylides

David L. Gray, A. Harris, D. Nason, 2010 .

Synthesis of 4-azepanones and heteroaromatic-fused azepines

S. Sakya, David L. Gray, Kees Pouwer, 2012 .

Measurement of atropisomer racemization kinetics using segmented flow technology.

Scot Mente, Jennifer E Davoren, Mark W Bundesmann, 2012, ACS medicinal chemistry letters.

Illness Phase as a Key Assessment and Intervention Window for Psychosis

Jared X. Van Snellenberg, J. Lieberman, J. Grinband, 2022, Biological psychiatry global open science.

PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial

J. Werth, S. Duvvuri, David L. Gray, 2020, Therapeutic advances in neurological disorders.

D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects.

R. Kozak, Patrick E. Trapa, David L. Gray, 2020, ACS chemical neuroscience.

Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson’s Disease following Oral Administration

S. Papapetropoulos, S. Duvvuri, David L. Gray, 2018, Neurodegenerative Diseases.

A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia

R. Balice-Gordon, R. Kozak, E. Arce, 2019, Journal of psychopharmacology.

Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation

Graham V. Williams, T. Kiss, M. Hajós, 2020, Frontiers in Pharmacology.

A novel dopamine D1 receptor agonist excites delay-dependent working memory-related neuronal firing in primate dorsolateral prefrontal cortex

A. Arnsten, Shengtao Yang, Min Wang, 2019, Neuropharmacology.

Dopamine D1 receptor-agonist interactions: A mutagenesis and homology modeling study.

Scot Mente, David L. Gray, S. Mente, 2015, Bioorganic & medicinal chemistry letters.

Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.

N. Barta, D. Ortwine, David L. Gray, 2010, Bioorganic & Medicinal Chemistry Letters.

Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.

David L. Gray, Simone Sciabola, G. Bai, 2016, Bioorganic & medicinal chemistry.

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia

R. Mailman, A. Arnsten, R. Girgis, 2017, Biological Psychiatry.

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity

Christopher H. Chatham, G. Honey, R. Balice-Gordon, 2020, The international journal of neuropsychopharmacology.

Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Rat Prefrontal Cortical Dopamine Response to Dual Acting Norepinephrine Reuptake Inhibitor and 5-HT1A Partial Agonist

T. Haske, N. Barta, David L. Gray, 2012, The AAPS Journal.

Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.

C. J. O’Donnell, David L. Gray, B. Campbell, 2011, Bioorganic & medicinal chemistry letters.

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

M. Ehlers, P. Tierney, R. Kozak, 2018, Nature Communications.

Pharmacoeconomic Considerations in CNS Drug Development

David L. Gray, 2014 .

Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.

D. Stone, J. Renger, S. Duvvuri, 2021, The Journal of clinical investigation.

Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.

N. Barta, David L. Gray, B. Campbell, 2009, Bioorganic & medicinal chemistry letters.

Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Rat Prefrontal Cortical Dopamine Response to Dual Acting Norepinephrine Reuptake Inhibitor and 5-HT1A Partial Agonist

T. Haske, N. Barta, David L. Gray, 2012, The AAPS Journal.

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease

E. Bézard, R. Kozak, S. Duvvuri, 2023, CNS & neurological disorders drug targets.